Duchenne Muscular Dystrophy Drugs Market Report

Europe Duchenne Muscular Dystrophy Drugs Market Size, Status and Forecast 2014-2026

  • POSTDATE：Oct 17, 2019
  • PAGES：220
  • REPORT CODE：GMM327362
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Duchenne Muscular Dystrophy Drugs market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 3.8% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Duchenne Muscular Dystrophy Drugs Market Segmentations:

    By Player:

    • Catabasis Pharmaceuticals

    • Santhera Pharmaceuticals

    • Pfizer

    • Summit Therapeutics

    • Acceleron Pharma

    • PTC Therapeutics

    • Nippon Shinyaku

    • Taiho Pharmaceutical

    • Italfarmaco

    • Janssen Pharmaceuticals

    • Nobelpharma

    • Marathon Pharmaceuticals

    • Eli Lilly

    • Sarepta Therapeutics

    • BioMarin Pharmaceutical

    • Capricor Therapeutics

    • Lexicon Pharmaceuticals

    • Bristol-Myers Squibb

    • Asklepios BioPharmaceuticals

    • Akashi Therapeutics

    By Type:

    • Exondys51

    • Translarna

    • Emflaza

    By End-User:

    • Hospitals

    • Home care settings

    • Clinics

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Duchenne Muscular Dystrophy Drugs Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Exondys51 from 2014 to 2026

    • 1.3.2 Europe Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Translarna from 2014 to 2026

    • 1.3.3 Europe Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Emflaza from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Hospitals from 2014 to 2026

    • 1.4.2 Europe Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Home care settings from 2014 to 2026

    • 1.4.3 Europe Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Clinics from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Duchenne Muscular Dystrophy Drugs Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Duchenne Muscular Dystrophy Drugs by Major Types

      • 3.4.1 Market Size and Growth Rate of Exondys51

      • 3.4.2 Market Size and Growth Rate of Translarna

      • 3.4.3 Market Size and Growth Rate of Emflaza

    4 Segmentation of Duchenne Muscular Dystrophy Drugs Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Duchenne Muscular Dystrophy Drugs by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Duchenne Muscular Dystrophy Drugs for Hospitals

      • 4.4.2 Market Size and Growth Rate of Duchenne Muscular Dystrophy Drugs for Home care settings

      • 4.4.3 Market Size and Growth Rate of Duchenne Muscular Dystrophy Drugs for Clinics

    5 Market Analysis by Major Regions

    • 5.1 Europe Duchenne Muscular Dystrophy Drugs Production Analysis by Top Regions

    • 5.2 Europe Duchenne Muscular Dystrophy Drugs Consumption Analysis by Top Regions

    • 5.3 Europe Duchenne Muscular Dystrophy Drugs Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Duchenne Muscular Dystrophy Drugs Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Duchenne Muscular Dystrophy Drugs Production, Import, Consumption and Export Analysis

      • 5.3.3 France Duchenne Muscular Dystrophy Drugs Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Duchenne Muscular Dystrophy Drugs Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Duchenne Muscular Dystrophy Drugs Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Duchenne Muscular Dystrophy Drugs Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Duchenne Muscular Dystrophy Drugs Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Duchenne Muscular Dystrophy Drugs Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Duchenne Muscular Dystrophy Drugs Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Duchenne Muscular Dystrophy Drugs Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Duchenne Muscular Dystrophy Drugs Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Duchenne Muscular Dystrophy Drugs Production, Import, Consumption and Export Analysis

    6 Product Circulation of Duchenne Muscular Dystrophy Drugs Market among Top Countries

    • 6.1 Top 5 Export Countries in Duchenne Muscular Dystrophy Drugs Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Duchenne Muscular Dystrophy Drugs Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Duchenne Muscular Dystrophy Drugs Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Duchenne Muscular Dystrophy Drugs Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Duchenne Muscular Dystrophy Drugs Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Duchenne Muscular Dystrophy Drugs Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Duchenne Muscular Dystrophy Drugs Landscape Analysis

    • 7.1 Germany Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major Types

    • 7.2 Germany Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major End-Users

    8. UK Duchenne Muscular Dystrophy Drugs Landscape Analysis

    • 8.1 UK Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major Types

    • 8.2 UK Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major End-Users

    9. France Duchenne Muscular Dystrophy Drugs Landscape Analysis

    • 9.1 France Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major Types

    • 9.2 France Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major End-Users

    10. Italy Duchenne Muscular Dystrophy Drugs Landscape Analysis

    • 10.1 Italy Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major Types

    • 10.2 Italy Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major End-Users

    11. Spain Duchenne Muscular Dystrophy Drugs Landscape Analysis

    • 11.1 Spain Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major Types

    • 11.2 Spain Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major End-Users

    12. Poland Duchenne Muscular Dystrophy Drugs Landscape Analysis

    • 12.1 Poland Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major Types

    • 12.2 Poland Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major End-Users

    13. Russia Duchenne Muscular Dystrophy Drugs Landscape Analysis

    • 13.1 Russia Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major Types

    • 13.2 Russia Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major End-Users

    14. Switzerland Duchenne Muscular Dystrophy Drugs Landscape Analysis

    • 14.1 Switzerland Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major Types

    • 14.2 Switzerland Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major End-Users

    15. Turkey Duchenne Muscular Dystrophy Drugs Landscape Analysis

    • 15.1 Turkey Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major Types

    • 15.2 Turkey Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Duchenne Muscular Dystrophy Drugs Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Duchenne Muscular Dystrophy Drugs Landscape Analysis by Top Countries

      • 16.3.1 Denmark Duchenne Muscular Dystrophy Drugs Market Volume and Growth Rate

      • 16.3.2 Finland Duchenne Muscular Dystrophy Drugs Market Volume and Growth Rate

      • 16.3.3 Norway Duchenne Muscular Dystrophy Drugs Market Volume and Growth Rate

      • 16.3.4 Sweden Duchenne Muscular Dystrophy Drugs Market Volume and Growth Rate

      • 16.3.6 Iceland Duchenne Muscular Dystrophy Drugs Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Duchenne Muscular Dystrophy Drugs Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Duchenne Muscular Dystrophy Drugs Landscape Analysis by Top Countries

      • 17.3.1 Belgium Duchenne Muscular Dystrophy Drugs Market Volume and Growth Rate

      • 17.3.2 Netherlands Duchenne Muscular Dystrophy Drugs Market Volume and Growth Rate

      • 17.3.3 Luxembourg Duchenne Muscular Dystrophy Drugs Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Duchenne Muscular Dystrophy Drugs Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Duchenne Muscular Dystrophy Drugs Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Duchenne Muscular Dystrophy Drugs Landscape Analysis by Top Countries

      • 18.3.1 Estonia Duchenne Muscular Dystrophy Drugs Market Volume and Growth Rate

      • 18.3.2 Latvia Duchenne Muscular Dystrophy Drugs Market Volume and Growth Rate

      • 18.3.3 Lithuania Duchenne Muscular Dystrophy Drugs Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Catabasis Pharmaceuticals

      • 19.1.1 Catabasis Pharmaceuticals Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 Santhera Pharmaceuticals

      • 19.2.1 Santhera Pharmaceuticals Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Pfizer

      • 19.3.1 Pfizer Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Summit Therapeutics

      • 19.4.1 Summit Therapeutics Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Acceleron Pharma

      • 19.5.1 Acceleron Pharma Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 PTC Therapeutics

      • 19.6.1 PTC Therapeutics Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Nippon Shinyaku

      • 19.7.1 Nippon Shinyaku Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 Taiho Pharmaceutical

      • 19.8.1 Taiho Pharmaceutical Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Italfarmaco

      • 19.9.1 Italfarmaco Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 Janssen Pharmaceuticals

      • 19.10.1 Janssen Pharmaceuticals Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    • 19.11 Nobelpharma

      • 19.11.1 Nobelpharma Company Profile and Development Status

      • 19.11.2 Market Performance

      • 19.11.3 Product and Service Introduction

    • 19.12 Marathon Pharmaceuticals

      • 19.12.1 Marathon Pharmaceuticals Company Profile and Development Status

      • 19.12.2 Market Performance

      • 19.12.3 Product and Service Introduction

    • 19.13 Eli Lilly

      • 19.13.1 Eli Lilly Company Profile and Development Status

      • 19.13.2 Market Performance

      • 19.13.3 Product and Service Introduction

    • 19.14 Sarepta Therapeutics

      • 19.14.1 Sarepta Therapeutics Company Profile and Development Status

      • 19.14.2 Market Performance

      • 19.14.3 Product and Service Introduction

    • 19.15 BioMarin Pharmaceutical

      • 19.15.1 BioMarin Pharmaceutical Company Profile and Development Status

      • 19.15.2 Market Performance

      • 19.15.3 Product and Service Introduction

    • 19.16 Capricor Therapeutics

      • 19.16.1 Capricor Therapeutics Company Profile and Development Status

      • 19.16.2 Market Performance

      • 19.16.3 Product and Service Introduction

    • 19.17 Lexicon Pharmaceuticals

      • 19.17.1 Lexicon Pharmaceuticals Company Profile and Development Status

      • 19.17.2 Market Performance

      • 19.17.3 Product and Service Introduction

    • 19.18 Bristol-Myers Squibb

      • 19.18.1 Bristol-Myers Squibb Company Profile and Development Status

      • 19.18.2 Market Performance

      • 19.18.3 Product and Service Introduction

    • 19.19 Asklepios BioPharmaceuticals

      • 19.19.1 Asklepios BioPharmaceuticals Company Profile and Development Status

      • 19.19.2 Market Performance

      • 19.19.3 Product and Service Introduction

    • 19.20 Akashi Therapeutics

      • 19.20.1 Akashi Therapeutics Company Profile and Development Status

      • 19.20.2 Market Performance

      • 19.20.3 Product and Service Introduction

    The List of Tables and Figures (Totals 113 Figures and 123 Tables)

    • Figure Product Picture

    • Figure Europe Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Exondys51 from 2014 to 2026

    • Figure Europe Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Translarna from 2014 to 2026

    • Figure Europe Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Emflaza from 2014 to 2026

    • Figure Europe Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Hospitals from 2014 to 2026

    • Figure Europe Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Home care settings from 2014 to 2026

    • Figure Europe Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate of Clinics from 2014 to 2026

    • Figure Germany Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure UK Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure France Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Duchenne Muscular Dystrophy Drugs Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Duchenne Muscular Dystrophy Drugs Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Duchenne Muscular Dystrophy Drugs

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Duchenne Muscular Dystrophy Drugs by Different Types from 2014 to 2026

    • Table Consumption Share of Duchenne Muscular Dystrophy Drugs by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of Exondys51

    • Figure Market Size and Growth Rate of Translarna

    • Figure Market Size and Growth Rate of Emflaza

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Duchenne Muscular Dystrophy Drugs by Different End-Users from 2014 to 2026

    • Table Consumption Share of Duchenne Muscular Dystrophy Drugs by Different End-Users from 2014 to 2026

    • Figure Market Size and Growth Rate of Hospitals

    • Figure Market Size and Growth Rate of Home care settings

    • Figure Market Size and Growth Rate of Clinics

    • Table Europe Duchenne Muscular Dystrophy Drugs Production by Major Regions

    • Table Europe Duchenne Muscular Dystrophy Drugs Production Share by Major Regions

    • Figure Europe Duchenne Muscular Dystrophy Drugs Production Share by Major Countries and Regions in 2014

    • Table Europe Duchenne Muscular Dystrophy Drugs Consumption by Major Regions

    • Table Europe Duchenne Muscular Dystrophy Drugs Consumption Share by Major Regions

    • Table Germany Duchenne Muscular Dystrophy Drugs Production, Import, Consumption and Export Analysis

    • Table UK Duchenne Muscular Dystrophy Drugs Production, Import, Consumption and Export Analysis

    • Table France Duchenne Muscular Dystrophy Drugs Production, Import, Consumption and Export Analysis

    • Table Italy Duchenne Muscular Dystrophy Drugs Production, Import, Consumption and Export Analysis

    • Table Spain Duchenne Muscular Dystrophy Drugs Production, Import, Consumption and Export Analysis

    • Table Poland Duchenne Muscular Dystrophy Drugs Production, Import, Consumption and Export Analysis

    • Table Russia Duchenne Muscular Dystrophy Drugs Production, Import, Consumption and Export Analysis

    • Table Switzerland Duchenne Muscular Dystrophy Drugs Production, Import, Consumption and Export Analysis

    • Table Turkey Duchenne Muscular Dystrophy Drugs Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Duchenne Muscular Dystrophy Drugs Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Duchenne Muscular Dystrophy Drugs Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Duchenne Muscular Dystrophy Drugs Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Duchenne Muscular Dystrophy Drugs Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Duchenne Muscular Dystrophy Drugs Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Duchenne Muscular Dystrophy Drugs Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Duchenne Muscular Dystrophy Drugs Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Duchenne Muscular Dystrophy Drugs Consumption by Types from 2014 to 2026

    • Table Germany Duchenne Muscular Dystrophy Drugs Consumption Share by Types from 2014 to 2026

    • Table Germany Duchenne Muscular Dystrophy Drugs Consumption by End-Users from 2014 to 2026

    • Table Germany Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users from 2014 to 2026

    • Table UK Duchenne Muscular Dystrophy Drugs Consumption by Types from 2014 to 2026

    • Table UK Duchenne Muscular Dystrophy Drugs Consumption Share by Types from 2014 to 2026

    • Table UK Duchenne Muscular Dystrophy Drugs Consumption by End-Users from 2014 to 2026

    • Table UK Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users from 2014 to 2026

    • Table France Duchenne Muscular Dystrophy Drugs Consumption by Types from 2014 to 2026

    • Table France Duchenne Muscular Dystrophy Drugs Consumption Share by Types from 2014 to 2026

    • Table France Duchenne Muscular Dystrophy Drugs Consumption by End-Users from 2014 to 2026

    • Table France Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Italy Duchenne Muscular Dystrophy Drugs Consumption by Types from 2014 to 2026

    • Table Italy Duchenne Muscular Dystrophy Drugs Consumption Share by Types from 2014 to 2026

    • Table Italy Duchenne Muscular Dystrophy Drugs Consumption by End-Users from 2014 to 2026

    • Table Italy Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Spain Duchenne Muscular Dystrophy Drugs Consumption by Types from 2014 to 2026

    • Table Spain Duchenne Muscular Dystrophy Drugs Consumption Share by Types from 2014 to 2026

    • Table Spain Duchenne Muscular Dystrophy Drugs Consumption by End-Users from 2014 to 2026

    • Table Spain Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Poland Duchenne Muscular Dystrophy Drugs Consumption by Types from 2014 to 2026

    • Table Poland Duchenne Muscular Dystrophy Drugs Consumption Share by Types from 2014 to 2026

    • Table Poland Duchenne Muscular Dystrophy Drugs Consumption by End-Users from 2014 to 2026

    • Table Poland Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Russia Duchenne Muscular Dystrophy Drugs Consumption by Types from 2014 to 2026

    • Table Russia Duchenne Muscular Dystrophy Drugs Consumption Share by Types from 2014 to 2026

    • Table Russia Duchenne Muscular Dystrophy Drugs Consumption by End-Users from 2014 to 2026

    • Table Russia Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Duchenne Muscular Dystrophy Drugs Consumption by Types from 2014 to 2026

    • Table Switzerland Duchenne Muscular Dystrophy Drugs Consumption Share by Types from 2014 to 2026

    • Table Switzerland Duchenne Muscular Dystrophy Drugs Consumption by End-Users from 2014 to 2026

    • Table Switzerland Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Duchenne Muscular Dystrophy Drugs Consumption by Types from 2014 to 2026

    • Table Turkey Duchenne Muscular Dystrophy Drugs Consumption Share by Types from 2014 to 2026

    • Table Turkey Duchenne Muscular Dystrophy Drugs Consumption by End-Users from 2014 to 2026

    • Table Turkey Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Duchenne Muscular Dystrophy Drugs Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Duchenne Muscular Dystrophy Drugs Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Duchenne Muscular Dystrophy Drugs Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Duchenne Muscular Dystrophy Drugs Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Duchenne Muscular Dystrophy Drugs Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Duchenne Muscular Dystrophy Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Duchenne Muscular Dystrophy Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Duchenne Muscular Dystrophy Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Duchenne Muscular Dystrophy Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Duchenne Muscular Dystrophy Drugs Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Duchenne Muscular Dystrophy Drugs Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Duchenne Muscular Dystrophy Drugs Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Duchenne Muscular Dystrophy Drugs Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Duchenne Muscular Dystrophy Drugs Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Duchenne Muscular Dystrophy Drugs Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Duchenne Muscular Dystrophy Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Duchenne Muscular Dystrophy Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Duchenne Muscular Dystrophy Drugs Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Duchenne Muscular Dystrophy Drugs Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Duchenne Muscular Dystrophy Drugs Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Duchenne Muscular Dystrophy Drugs Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Duchenne Muscular Dystrophy Drugs Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Duchenne Muscular Dystrophy Drugs Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Duchenne Muscular Dystrophy Drugs Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Duchenne Muscular Dystrophy Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Duchenne Muscular Dystrophy Drugs Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Duchenne Muscular Dystrophy Drugs Market Volume and Growth Rate from 2014 to 2026

    • Table Company Profile and Development Status of Catabasis Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Catabasis Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Catabasis Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Catabasis Pharmaceuticals

    • Table Product and Service Introduction of Catabasis Pharmaceuticals

    • Table Company Profile and Development Status of Santhera Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Santhera Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Santhera Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Santhera Pharmaceuticals

    • Table Product and Service Introduction of Santhera Pharmaceuticals

    • Table Company Profile and Development Status of Pfizer

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer

    • Figure Sales and Growth Rate Analysis of Pfizer

    • Figure Revenue and Market Share Analysis of Pfizer

    • Table Product and Service Introduction of Pfizer

    • Table Company Profile and Development Status of Summit Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Summit Therapeutics

    • Figure Sales and Growth Rate Analysis of Summit Therapeutics

    • Figure Revenue and Market Share Analysis of Summit Therapeutics

    • Table Product and Service Introduction of Summit Therapeutics

    • Table Company Profile and Development Status of Acceleron Pharma

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Acceleron Pharma

    • Figure Sales and Growth Rate Analysis of Acceleron Pharma

    • Figure Revenue and Market Share Analysis of Acceleron Pharma

    • Table Product and Service Introduction of Acceleron Pharma

    • Table Company Profile and Development Status of PTC Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of PTC Therapeutics

    • Figure Sales and Growth Rate Analysis of PTC Therapeutics

    • Figure Revenue and Market Share Analysis of PTC Therapeutics

    • Table Product and Service Introduction of PTC Therapeutics

    • Table Company Profile and Development Status of Nippon Shinyaku

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Nippon Shinyaku

    • Figure Sales and Growth Rate Analysis of Nippon Shinyaku

    • Figure Revenue and Market Share Analysis of Nippon Shinyaku

    • Table Product and Service Introduction of Nippon Shinyaku

    • Table Company Profile and Development Status of Taiho Pharmaceutical

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Taiho Pharmaceutical

    • Figure Sales and Growth Rate Analysis of Taiho Pharmaceutical

    • Figure Revenue and Market Share Analysis of Taiho Pharmaceutical

    • Table Product and Service Introduction of Taiho Pharmaceutical

    • Table Company Profile and Development Status of Italfarmaco

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Italfarmaco

    • Figure Sales and Growth Rate Analysis of Italfarmaco

    • Figure Revenue and Market Share Analysis of Italfarmaco

    • Table Product and Service Introduction of Italfarmaco

    • Table Company Profile and Development Status of Janssen Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Janssen Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Janssen Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Janssen Pharmaceuticals

    • Table Product and Service Introduction of Janssen Pharmaceuticals

    • Table Company Profile and Development Status of Nobelpharma

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Nobelpharma

    • Figure Sales and Growth Rate Analysis of Nobelpharma

    • Figure Revenue and Market Share Analysis of Nobelpharma

    • Table Product and Service Introduction of Nobelpharma

    • Table Company Profile and Development Status of Marathon Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Marathon Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Marathon Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Marathon Pharmaceuticals

    • Table Product and Service Introduction of Marathon Pharmaceuticals

    • Table Company Profile and Development Status of Eli Lilly

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Eli Lilly

    • Figure Sales and Growth Rate Analysis of Eli Lilly

    • Figure Revenue and Market Share Analysis of Eli Lilly

    • Table Product and Service Introduction of Eli Lilly

    • Table Company Profile and Development Status of Sarepta Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sarepta Therapeutics

    • Figure Sales and Growth Rate Analysis of Sarepta Therapeutics

    • Figure Revenue and Market Share Analysis of Sarepta Therapeutics

    • Table Product and Service Introduction of Sarepta Therapeutics

    • Table Company Profile and Development Status of BioMarin Pharmaceutical

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of BioMarin Pharmaceutical

    • Figure Sales and Growth Rate Analysis of BioMarin Pharmaceutical

    • Figure Revenue and Market Share Analysis of BioMarin Pharmaceutical

    • Table Product and Service Introduction of BioMarin Pharmaceutical

    • Table Company Profile and Development Status of Capricor Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Capricor Therapeutics

    • Figure Sales and Growth Rate Analysis of Capricor Therapeutics

    • Figure Revenue and Market Share Analysis of Capricor Therapeutics

    • Table Product and Service Introduction of Capricor Therapeutics

    • Table Company Profile and Development Status of Lexicon Pharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Lexicon Pharmaceuticals

    • Figure Sales and Growth Rate Analysis of Lexicon Pharmaceuticals

    • Figure Revenue and Market Share Analysis of Lexicon Pharmaceuticals

    • Table Product and Service Introduction of Lexicon Pharmaceuticals

    • Table Company Profile and Development Status of Bristol-Myers Squibb

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bristol-Myers Squibb

    • Figure Sales and Growth Rate Analysis of Bristol-Myers Squibb

    • Figure Revenue and Market Share Analysis of Bristol-Myers Squibb

    • Table Product and Service Introduction of Bristol-Myers Squibb

    • Table Company Profile and Development Status of Asklepios BioPharmaceuticals

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Asklepios BioPharmaceuticals

    • Figure Sales and Growth Rate Analysis of Asklepios BioPharmaceuticals

    • Figure Revenue and Market Share Analysis of Asklepios BioPharmaceuticals

    • Table Product and Service Introduction of Asklepios BioPharmaceuticals

    • Table Company Profile and Development Status of Akashi Therapeutics

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Akashi Therapeutics

    • Figure Sales and Growth Rate Analysis of Akashi Therapeutics

    • Figure Revenue and Market Share Analysis of Akashi Therapeutics

    • Table Product and Service Introduction of Akashi Therapeutics

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US